Inpharma Weekly

, Volume 925, Issue 1, pp 11–11 | Cite as

New agent competes with triple therapy in H. pylori eradication

  • Robert Short
Newsletter Article
  • 1 Downloads

Abstract

With recent results showing that Helicobacter pylori eradication really does prevent stomach ulcers, Glaxo could be onto a winner with their new agent, ranitidine bismuth citrate. This single chemical molecule has been developed for use as monotherapy or in combination with antibacterials, and is likely to provide fierce competition for the currently-used triple therapy. Glaxo plans to file for regulatory approval for this drug later this year.

Keywords

Duodenal Ulcer Ranitidine Triple Therapy Pylorus Eradication Eradication Therapy 

Copyright information

© Adis International Ltd 1994

Authors and Affiliations

  • Robert Short

There are no affiliations available

Personalised recommendations